SCHEMBL2219484

SCHEMBL2219484

O=C(O)c1cnc(Cc2ccccc2)cn1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 8/20 0.49
HCAR2 Q8TDS4 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 3/20 0.44
ASPH Q12797 3/20 0.44
RIOX2 Q8IUF8 3/20 0.44
KDM8 Q8N371 3/20 0.44
BRD4 O60885 2/20 0.44
LMNA P02545 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
P4HA1 P13674 1/20 0.40
MIF P14174 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2217065 0.91 PLA2G10 (0.49) P4HTMHCAR2ALDH1A1HPGDALOX15
SCHEMBL12442596 0.86 LMNA (0.47) P4HTMALDH1A1BRD4LMNA
SCHEMBL27072915 0.82 CALM1 (0.55) ALDH1A1LMNAL3MBTL1
SCHEMBL6434986 0.76 P4HTM (0.62) P4HTMHCAR2ALDH1A1ALOX15KDM4E
SCHEMBL17663927 0.75 LDHA (0.51) P4HTMALDH1A1HPGDHSD17B10LMNA
Hydrochloric Acid SCHEMBL11633575 0.75 P4HTM (0.61) P4HTMHCAR2ALDH1A1ALOX15KDM4E
SCHEMBL23680085 0.75 KDM4E (0.43) P4HTMHCAR2ALDH1A1HPGDALOX15
SCHEMBL28291166 0.74 BRD4 (0.50) P4HTMHCAR2ALDH1A1HPGDALOX15
SCHEMBL18763010 0.73 TP53 (0.46) ALDH1A1BRD4LMNAL3MBTL1
SCHEMBL20121341 0.73 SIRT6 (0.44) P4HTMHCAR2ALDH1A1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2007-04-05 US claimed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US claimed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US claimed
US-20110177612-A1 Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders ARENA PHARMACEUTICALS, INC. 2011-07-21 US disclosed
US-7829298-B2 Human G protein-coupled receptors for metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2010-11-09 US disclosed
US-20080139628-A1 Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists ARENA PHARMACEUTICALS, INC. (US) 2008-06-12 US disclosed
CN-101076331-A Compositions comprising nicotinic acid receptor partial agonists for the treatment of rubeosis and lipid-related disorders ARENA PHARM INC (US) 2007-11-21 CN disclosed
EP-1811996-A1 COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS Arena Pharmaceuticals, Inc. (US) 2007-08-01 EP disclosed
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2007-04-05 US disclosed
WO-2006052569-A1 COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS ARENA PHARMACEUTICALS, INC. (US) 2006-05-18 WO disclosed
US-20050154029-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-07-14 US disclosed
US-6902902-B2 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-06-07 US disclosed
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2005-01-06 US disclosed
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders ARENA PHARMACEUTICALS, INC. (US) 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154029-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR P4HTM 4141/4885HCAR2 41/4885ALDH1A1 2465/4885
US-20070079392-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR P4HTM 4141/4885HCAR2 41/4885ALDH1A1 2465/4885
US-20080139628-A1 Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists FFAR1, FFAR2, FFAR3 P4HTM 2523/4885HCAR2 11/4885ALDH1A1 1861/4885
US-20050004178-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR P4HTM 4141/4885HCAR2 41/4885ALDH1A1 2465/4885
US-20040142377-A1 Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders GPR119, ADIPOR2, GCGR P4HTM 4141/4885HCAR2 41/4885ALDH1A1 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.